September 16, 2022 7:58am
News: Intellia Therapeutics (NTLA pre-open indication +$7.42) and Regeneron Pharmaceuticals (REGN) announced positive interim results from an ongoing P1 clinical trial of NTLA-2001, an investigational in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis.
(https://finance.yahoo.com/news/intellia-regeneron-announce-initial-data-111500506.html )
Indications: 2 Positive Indication, 1 Negative Indication and 1 Pump/Promote (BSTG – the usual suspect)
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
More frequently right than consequentially wrong; there is VALUE out there. What I provide is an intelligence daily.
The 8:00 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.72% or (-225 points), S&P futures are DOWN -0.82% (-32 points) and NASDAQ futures are DOWN -0.96% (-115 points) early in the pre-open – so far,
U.S. stock futures are falling on Friday as “the street” heads toward a big losing week,
European markets were trading lower,
Asia-Pacific markets also fall as China’s economic data accelerated in August.
Henry’omics:
Indexes dropped in choppy trading on Thursday as investors mulled over several economic reports that showed a muddy picture of the U.S. economy.
The Dow closed DOWN -173.07 points (-0.56 %) the S&P closed DOWN -44.69 points (-1.13 %) while the Nasdaq closed DOWN -167.32 points (-1.43 %)
All three indexes are on pace to notch their fourth (4th) losing week in five (5). The Dow has declined 3.7% this week, while the S&P 500 is 4.08% lower and Nasdaq is down 4.62%, headed toward its worst weekly loss since June.
Economic Data Docket: consumer sentiment data on 10 a.m. ET
RegMed Investors’ (RMi) closing bell: “musical chairs until the melody stops. Gene editors are feeling the tailwinds.” … https://www.regmedinvestors.com/articles/12605
Ebb and flow:
Q3/22 – September – 1 holiday, 7 positive and 3 negative closes
• August – 1 neutral, 11 positive and 11 negative closes
• July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive Indication:
CRISPR Therapeutics (CRSP) closed up +$2.82 to $75.01 after Wednesday’s +$0.73, Tuesday’s -$2.27, Monday’s +$2.86 and last Friday’s +$0.69 with a positive +$0.37 or +0.49% pre-open indication,
Intellia Therapeutics (NTLA) closed up +$4.70 to $68.58 after Wednesday’s +$0.73, Tuesday’s -$2.05 and Monday’s +$0.76 and Friday’s +$3.72 with a positive +$7.42 or +10.82% pre-open indication <on new in title>,
Negative Indication:
Beam Therapeutics (BEAM) closed up +$3.66 to $60.49 after Wednesday’s +$3.50 and Tuesday’s -$4.25 with a negative -$1.49 or -.46% pre-open indication
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed down -$0.19 with 717 shares traded after Wednesday’s +$0.15 with 2,101 shares traded, Tuesday’s -$0.30 with 500 shares traded, Monday’s -$0.10 with 442 shares traded, and last Friday’s +$0.06 with 3,600 shares traded, <3-month average = 1,780>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
- How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
- Who and WHAT are funding the “spikes” in volume and share price?
- What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: Are we, investors due for another DEEP dive in our cell and gene therapy universe as indexes WEAKEN?
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
As I continually question, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”
That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
